LOX and obesity due to melanocortin 4 receptor deficiency: NAH derivatives with anti-obesity activity and improved safety profiles, dual COX/LOX-modulating NAHs and β-amino-NAHs acting as DPP-4 inhibitors illustrate the versatility of this scaffold in addressing complex, multifactorial diseases [25,26,27].